---
title: "Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688266.SH.md"
symbol: "688266.SH"
name: "Suzhou Zelgen Biopharmaceuticals Co., Ltd"
industry: "Biotechnology"
datetime: "2026-05-20T08:01:53.679Z"
locales:
  - [en](https://longbridge.com/en/quote/688266.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688266.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688266.SH.md)
---

# Suzhou Zelgen Biopharmaceuticals Co., Ltd (688266.SH)

## Company Overview

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection. In addition, the company is developing drug candidates in Phase I/II clinical trial stages consisting of donafenib tablets for liver cancer and anti-tumor immunotherapy; gecacitinib hydrochloride cream for mild to moderate alopecia areata and atopic dermatitis, and nonsegmental vitiligo; ZG19018 and ZG2001 tablets for KRAS G12C and KRAS mutation late-stage solid tumors; and ZG005, ZGGS18, ZGGS15, ZG0895, and ZG006 powders for injections for late-stage solid tumors.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.zelgen.com](https://www.zelgen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.27)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 161.37% |  |
| Net Profit YoY | 493.33% |  |
| P/B Ratio | 15.35 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 26337580654.74 |  |
| Revenue | 1550987863.37 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 33.88% | A |
| Profit Margin | 32.16% | A |
| Gross Margin | 97.01% | A |
| Revenue YoY | 161.37% | A |
| Net Profit YoY | 493.33% | A |
| Total Assets YoY | 26.41% | A |
| Net Assets YoY | 39.99% | A |
| Cash Flow Margin | 163.66% | B |
| OCF YoY | 161.37% | A |
| Turnover | 0.47 | C |
| Gearing Ratio | 53.56% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Suzhou Zelgen Biopharmaceuticals Co., Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "161.37%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "493.33%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "15.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "26337580654.74",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1550987863.37",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "33.88%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "32.16%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "97.01%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "161.37%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "493.33%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "26.41%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "39.99%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "163.66%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "161.37%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "53.56%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 52.80 | 23/81 | 55.97 | 55.29 | 53.37 |
| PB | 15.35 | 72/81 | 24.88 | 23.47 | 20.85 |
| PS (TTM) | 16.98 | 65/81 | 48.60 | 37.80 | 32.01 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-19T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 100.07 |
| Highest Target | 161.08 |
| Lowest Target | 135.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688266.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688266.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688266.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**